Arena Pharmaceuticals (NASDAQ:ARNA) released its earnings results on Thursday. The biopharmaceutical company reported ($1.46) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.32) by ($0.14), RTT News reports. Arena Pharmaceuticals had a return on equity of 53.92% and a net margin of 72.84%. The business had revenue of $1.35 million for the quarter, compared to analyst estimates of $2.06 million. During the same quarter in the previous year, the firm posted ($0.70) EPS. The business’s revenue for the quarter was down 62.2% on a year-over-year basis.
Shares of ARNA traded down $0.83 on Friday, reaching $47.40. The stock had a trading volume of 743,200 shares, compared to its average volume of 468,723. The firm has a 50-day moving average of $48.02 and a 200 day moving average of $53.52. The company has a quick ratio of 36.51, a current ratio of 36.51 and a debt-to-equity ratio of 0.04. Arena Pharmaceuticals has a twelve month low of $31.97 and a twelve month high of $64.48. The firm has a market capitalization of $2.45 billion, a PE ratio of -16.07 and a beta of 1.54.
In other Arena Pharmaceuticals news, EVP Steven W. Spector sold 31,457 shares of the firm’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $50.72, for a total value of $1,595,499.04. Following the transaction, the executive vice president now directly owns 22,964 shares of the company’s stock, valued at $1,164,734.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Vincent Aurentz sold 65,000 shares of the firm’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $50.72, for a total value of $3,296,800.00. Following the completion of the transaction, the vice president now directly owns 25,000 shares in the company, valued at $1,268,000. The disclosure for this sale can be found here. Company insiders own 2.73% of the company’s stock.
Arena Pharmaceuticals Company Profile
Arena Pharmaceuticals, Inc, a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include ralinepag (APD811), which is in Phase III trial to treat pulmonary arterial hypertension; etrasimod (APD334) for ulcerative colitis, and Crohn's disease, as well as for atopic dermatitis and other indications; and Olorinab (APD371), which is in Phase II trial for the treatment of gastrointestinal pain.
See Also: Buy-Side Analysts
Receive News & Ratings for Arena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.